Cargando…
An introduction to insulin use in type 2 diabetes mellitus
The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AOSIS
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157446/ https://www.ncbi.nlm.nih.gov/pubmed/37132569 http://dx.doi.org/10.4102/safp.v65i1.5702 |
_version_ | 1785036754760237056 |
---|---|
author | Coetzee, Ankia |
author_facet | Coetzee, Ankia |
author_sort | Coetzee, Ankia |
collection | PubMed |
description | The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM in South Africa. Early, multifactorial intervention remains ideal, but glucose, blood pressure and cholesterol values remain above target in many countries. Barriers to achieving glucose control in South Africa include the healthcare provider’s being unfamiliar with the practicalities of insulin administration, initiation and titration. This article highlights these gaps and offers pragmatic solutions to overcome them. |
format | Online Article Text |
id | pubmed-10157446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AOSIS |
record_format | MEDLINE/PubMed |
spelling | pubmed-101574462023-05-05 An introduction to insulin use in type 2 diabetes mellitus Coetzee, Ankia S Afr Fam Pract (2004) CPD Article The benefits of the newer antidiabetic agents available for managing type 2 diabetes mellitus (T2DM) remain indisputable, but many patients will require insulin therapy in the disease course. Given the limited access to newer antidiabetic agents, insulin remains a standard treatment modality in T2DM in South Africa. Early, multifactorial intervention remains ideal, but glucose, blood pressure and cholesterol values remain above target in many countries. Barriers to achieving glucose control in South Africa include the healthcare provider’s being unfamiliar with the practicalities of insulin administration, initiation and titration. This article highlights these gaps and offers pragmatic solutions to overcome them. AOSIS 2023-04-20 /pmc/articles/PMC10157446/ /pubmed/37132569 http://dx.doi.org/10.4102/safp.v65i1.5702 Text en © 2023. The Authors https://creativecommons.org/licenses/by/4.0/Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License. |
spellingShingle | CPD Article Coetzee, Ankia An introduction to insulin use in type 2 diabetes mellitus |
title | An introduction to insulin use in type 2 diabetes mellitus |
title_full | An introduction to insulin use in type 2 diabetes mellitus |
title_fullStr | An introduction to insulin use in type 2 diabetes mellitus |
title_full_unstemmed | An introduction to insulin use in type 2 diabetes mellitus |
title_short | An introduction to insulin use in type 2 diabetes mellitus |
title_sort | introduction to insulin use in type 2 diabetes mellitus |
topic | CPD Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157446/ https://www.ncbi.nlm.nih.gov/pubmed/37132569 http://dx.doi.org/10.4102/safp.v65i1.5702 |
work_keys_str_mv | AT coetzeeankia anintroductiontoinsulinuseintype2diabetesmellitus AT coetzeeankia introductiontoinsulinuseintype2diabetesmellitus |